

PublisherInfo		
PublisherName	:	BioMed Central
PublisherLocation	:	London
PublisherImprintName	:	BioMed Central

Cyclin D₁ in breast cancer is not associated with Ki67 but with ER

ArticleInfo		
ArticleID	:	3778
ArticleDOI	:	10.1186/bcr-2001-68466
ArticleCitationID	:	68466
ArticleSequenceNumber	:	50
ArticleCategory	:	Paper Report
ArticleFirstPage	:	1
ArticleLastPage	:	3
ArticleHistory	:	RegistrationDate : 2001-8-20 Received : 2001-7-30 Accepted : 2001-8-20 OnlineDate : 2001-9-13
ArticleCopyright	:	Biomed Central Ltd2001

ArticleGrants	:	
ArticleContext	:	1305833

George Skliris,^{Affl}

Affl University of Leeds, UK

Keywords

Cancer, cyclin D₁, immunohistochemistry, Ki67, normal breast, oestrogen receptor

Context

D-type cyclins are implicated in cell cycle regulation. The cyclin D₁ gene is amplified in 15-20% of breast cancers while the protein is overexpressed in 50% of these cancers (see Additional information [1]). Overexpression of cyclin D₁ has been linked with oestrogen receptor (ER) α , because it can stimulate transcriptional functions in the absence of oestrogen (see Additional information [2]). A negative association in normal breast has been reported for ER α and Ki67 (a proliferation marker), although this relationship changes in many precancerous and ER-positive cancers. Therefore, the aim of the study was to investigate the interaction between cyclin D₁, ER and Ki67 in normal and malignant breast material.

Significant findings

The mean percentage of ER-positive cells in normal breast tissues was 20%. Approximately 50% of the cyclin-D₁-positive cells coexpressed ER. However, cyclin-D₁-positive cells were detected in 70% of ER-positive invasive ductal carcinomas (IDCs) and in 30% of ER-negative IDCs. In normal breast tissues, Ki67-positive cells accounted for 3% of the epithelial cells while only 0.3% contained cyclin D₁. In benign breast lesions no clear outcome was detected for cyclin D₁ and Ki67. Invasive cancers showed a higher percentage of Ki67-positive cells than normal tissue and this was significantly higher in ER-negative than in ER-positive carcinomas. Overall a positive correlation between cyclin D₁ and ER-positive cells was detected in normal and cancerous breast tissues, while a negative association was detected between cyclin D₁ and Ki67.

Comments

Cyclin D₁ overexpression has been associated with low grade ER-positive breast cancers (see Additional information [3]). In this study no cyclin D₁ positivity was detected in ER-negative breast cancers that contained a high percentage of Ki67-positive cells. A number of studies indicate that cyclin D₁ overexpression increases progressively from normal breast epithelium to atypical ductal hyperplasia (ADH), to ductal carcinoma *in situ* (DCIS) and to invasive cancers respectively (see Additional information [4,5]). The authors observed that cyclin D₁ was higher within in situ proliferations than in normal breasts, while in ADH cases similar values to those measured in ER-positive DCIS were seen. Therefore, they concluded that cyclin D₁ was not the ideal marker for separating benign from malignant breast lesions. Future studies should investigate further the interactions of cyclin D₁ and Ki67 expression in larger cohorts and include other histological carcinoma types.

Methods

Dual immunofluorescence immunohistochemistry

Additional information

1. Barnes DM: **Cyclin D1 in mammary carcinoma.** *J Pathol* 1998, **181**:267-269 ([PubMed abstract](#)).
2. Zwijsen RML, Wientjens E, Klompaker R, van der Sman J, Bernards R, Michalides RJAM: **CDK-independent activation of oestrogen receptor by cyclin D1.** *Cell* 1997, **88**:405-415 ([PubMed abstract](#)).
3. van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP: **Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value.** *Am J Pathol* 1997, **150**:705-711 ([PubMed abstract](#)).
4. Alle KM, Henshall SM, Field AS, Sutherland RL: **Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast.** *Clin Cancer Res* 1998, **4**:847-854 ([PubMed abstract](#)).

5. Zhu XL, Hartwick W, Rohan T, Kandel R: **Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma.** *Mod Pathol* 1998, **11**:1082-1088 (PubMed abstract).

References

1. Shoker BS, Jarvis C, Davies MPA, Iqbal M, Sibson DR, Sloane JP: Immunodetectable cyclin D₁ is associated with oestrogen receptor but not Ki67 in normal, cancer and precancerous breast lesions. *Br J Cancer* . 2001, **84**: 1064-1068.